Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 19/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 11/20 | 1.00 |
| ▸ | UBE2I | P63279 | 1/20 | 0.66 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.66 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.66 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.66 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929969 | 0.87 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL928848 | 0.85 | ADORA2A (0.74) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL929123 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL928217 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL930244 | 0.85 | ADORA2A (0.77) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL928918 | 0.83 | ADORA2A (0.72) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL930439 | 0.83 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BUBE2I | |
| SCHEMBL930772 | 0.82 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL929502 | 0.82 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL930823 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | claimed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| EP-1722798-B1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | ADORA3, P2RY10, ADORA2A | ADORA2A 3/4885ADORA1 4/4885ADORA3 1/4885 |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.